Alcon HAWK

Active Clinical Trials // Feb 14 2017

sponsored by Alcon

(this trial is no longer enrolling)

A two-year, randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration.

Principal Investigator: Michael Altaweel

Coordinator: Angie Adler

Primary Objective: To demonstrate that RTH258 (3 mg and 6 mg) is not inferior to aflibercept (2 mg) with respect to the change in best-corrected visual acuity (BCVA) from Baseline to Week 48

Inclusion Criteria:

  1. Subjects must give written informed consent before any study related procedures are performed
  1. Subjects must be 50 years of age or older at Screening
  1. Active CNV lesions secondary to AMD that affect the fovea (including retinal angiomatous proliferation [RAP] lesions with a CNV component) in the study eye, confirmed by the Central Reading Center (CRC) at Screening
  1. Total area of CNV (including both classic and occult components) must comprise > 50% of the total lesion area in the study eye, confirmed by the CRC at Screening
  1. Intra and/or subretinal fluid affecting the center of the fovea of the study eye, confirmed by the CRC at Screening
  1. BCVA between 78 and 23 letters, inclusive, in the study eye at Baseline using Early Treatment Diabetic Retinopathy Study (ETDRS) testing

Please contact the study coordinator with questions: Angie Adler 608-265-7557